A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
Identifieur interne : 000079 ( PubMed/Curation ); précédent : 000078; suivant : 000080A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
Auteurs : Laurie K. Mischley [États-Unis] ; James B. Leverenz [États-Unis] ; Richard C. Lau [États-Unis] ; Nayak L. Polissar [États-Unis] ; Moni B. Neradilek [États-Unis] ; Ali Samii [États-Unis] ; Leanna J. Standish [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
Depletion of reduced glutathione is associated with PD and glutathione augmentation has been proposed as a disease-modifying strategy. The aim of this study was to determine the safety and tolerability of intranasal reduced glutathione in individuals with PD.
DOI: 10.1002/mds.26351
PubMed: 26230671
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000079
Links to Exploration step
pubmed:26230671Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.</title><author><name sortKey="Mischley, Laurie K" sort="Mischley, Laurie K" uniqKey="Mischley L" first="Laurie K" last="Mischley">Laurie K. Mischley</name><affiliation wicri:level="1"><nlm:affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bastyr University Research Institute, Kenmore, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B" last="Leverenz">James B. Leverenz</name><affiliation wicri:level="1"><nlm:affiliation>Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio</wicri:regionArea></affiliation></author><author><name sortKey="Lau, Richard C" sort="Lau, Richard C" uniqKey="Lau R" first="Richard C" last="Lau">Richard C. Lau</name><affiliation wicri:level="1"><nlm:affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bastyr University Research Institute, Kenmore, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Polissar, Nayak L" sort="Polissar, Nayak L" uniqKey="Polissar N" first="Nayak L" last="Polissar">Nayak L. Polissar</name><affiliation wicri:level="1"><nlm:affiliation>The Mountain-Whisper Light, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Mountain-Whisper Light, Seattle, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Neradilek, Moni B" sort="Neradilek, Moni B" uniqKey="Neradilek M" first="Moni B" last="Neradilek">Moni B. Neradilek</name><affiliation wicri:level="1"><nlm:affiliation>The Mountain-Whisper Light, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Mountain-Whisper Light, Seattle, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Washington; Northwest PADRECC at the Seattle VA Medical Center, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington; Northwest PADRECC at the Seattle VA Medical Center, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Standish, Leanna J" sort="Standish, Leanna J" uniqKey="Standish L" first="Leanna J" last="Standish">Leanna J. Standish</name><affiliation wicri:level="1"><nlm:affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bastyr University Research Institute, Kenmore, Washington</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26230671</idno><idno type="pmid">26230671</idno><idno type="doi">10.1002/mds.26351</idno><idno type="wicri:Area/PubMed/Corpus">000079</idno><idno type="wicri:Area/PubMed/Curation">000079</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.</title><author><name sortKey="Mischley, Laurie K" sort="Mischley, Laurie K" uniqKey="Mischley L" first="Laurie K" last="Mischley">Laurie K. Mischley</name><affiliation wicri:level="1"><nlm:affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bastyr University Research Institute, Kenmore, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Leverenz, James B" sort="Leverenz, James B" uniqKey="Leverenz J" first="James B" last="Leverenz">James B. Leverenz</name><affiliation wicri:level="1"><nlm:affiliation>Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio</wicri:regionArea></affiliation></author><author><name sortKey="Lau, Richard C" sort="Lau, Richard C" uniqKey="Lau R" first="Richard C" last="Lau">Richard C. Lau</name><affiliation wicri:level="1"><nlm:affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bastyr University Research Institute, Kenmore, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Polissar, Nayak L" sort="Polissar, Nayak L" uniqKey="Polissar N" first="Nayak L" last="Polissar">Nayak L. Polissar</name><affiliation wicri:level="1"><nlm:affiliation>The Mountain-Whisper Light, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Mountain-Whisper Light, Seattle, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Neradilek, Moni B" sort="Neradilek, Moni B" uniqKey="Neradilek M" first="Moni B" last="Neradilek">Moni B. Neradilek</name><affiliation wicri:level="1"><nlm:affiliation>The Mountain-Whisper Light, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Mountain-Whisper Light, Seattle, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Washington; Northwest PADRECC at the Seattle VA Medical Center, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Washington; Northwest PADRECC at the Seattle VA Medical Center, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Standish, Leanna J" sort="Standish, Leanna J" uniqKey="Standish L" first="Leanna J" last="Standish">Leanna J. Standish</name><affiliation wicri:level="1"><nlm:affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bastyr University Research Institute, Kenmore, Washington</wicri:regionArea></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depletion of reduced glutathione is associated with PD and glutathione augmentation has been proposed as a disease-modifying strategy. The aim of this study was to determine the safety and tolerability of intranasal reduced glutathione in individuals with PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="In-Data-Review"><PMID Version="1">26230671</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>17</Day></DateCreated><DateRevised><Year>2015</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1696-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26351</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depletion of reduced glutathione is associated with PD and glutathione augmentation has been proposed as a disease-modifying strategy. The aim of this study was to determine the safety and tolerability of intranasal reduced glutathione in individuals with PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty individuals with PD were randomized to either placebo (saline), 300 mg/day, or 600 mg/day of intranasal glutathione in three divided daily doses. Follow-up visits included side effect screening of PD symptoms and cognition, blood chemistry, sinus irritation, and hyposmia. Tolerability was measured by frequency and severity of reported adverse events, compliance, and withdrawals from the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After 3 months, there were no substantial differences between groups in the number of adverse events reported or observed among all safety measures assessed. All groups met tolerability criteria.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data support the safety and tolerability of intranasal glutathione in this population. Pharmacokinetic and dose-finding studies are warranted. © 2015 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mischley</LastName><ForeName>Laurie K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nutritional Sciences, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polissar</LastName><ForeName>Nayak L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>The Mountain-Whisper Light, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neradilek</LastName><ForeName>Moni B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>The Mountain-Whisper Light, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samii</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington; Northwest PADRECC at the Seattle VA Medical Center, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Standish</LastName><ForeName>Leanna J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Bastyr University Research Institute, Kenmore, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AT004404</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Otolaryngol Head Neck Surg. 2002 Jan;126(1):41-7</RefSource><PMID Version="1">11821764</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arq Neuropsiquiatr. 2013 Aug;71(8):527-32</RefSource><PMID Version="1">23982010</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1992 Dec;51(4):835-42</RefSource><PMID Version="1">1336827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Pharmacol. 1992;43(6):667-9</RefSource><PMID Version="1">1362956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1994 Sep;36(3):348-55</RefSource><PMID Version="1">8080242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Invest. 1996;14(3):202-10</RefSource><PMID Version="1">8630680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1159-70</RefSource><PMID Version="1">8938817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 1997;104(6-7):661-77</RefSource><PMID Version="1">9444566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Brain Res Rev. 1997 Dec;25(3):335-58</RefSource><PMID Version="1">9495562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Zhonghua Gan Zang Bing Za Zhi. 2008 Jul;16(7):487-9</RefSource><PMID Version="1">18647523</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2008 Aug;65(8):1074-80</RefSource><PMID Version="1">18695057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 May 15;24(7):979-83</RefSource><PMID Version="1">19230029</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2010 Jul;24(7):2533-45</RefSource><PMID Version="1">20228251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Apr;26(5):813-8</RefSource><PMID Version="1">21437987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oxid Med Cell Longev. 2012;2012:240146</RefSource><PMID Version="1">22701755</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Mar;28(3):311-8</RefSource><PMID Version="1">23436720</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Altern Complement Med. 2013 May;19(5):459-63</RefSource><PMID Version="1">23240940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 2013 Aug 2;587(15):2291-8</RefSource><PMID Version="1">23773928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1993 Jan 21;328(3):176-83</RefSource><PMID Version="1">8417384</PMID></CommentsCorrections></CommentsCorrectionsList><OtherID Source="NLM">NIHMS706325 [Available on 10/01/16]</OtherID><OtherID Source="NLM">PMC4609266 [Available on 10/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidant</Keyword><Keyword MajorTopicYN="N">deficiency</Keyword><Keyword MajorTopicYN="N">glutathione</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">nutrition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26230671</ArticleId><ArticleId IdType="doi">10.1002/mds.26351</ArticleId><ArticleId IdType="pmc">PMC4609266</ArticleId><ArticleId IdType="mid">NIHMS706325</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000079 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000079 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26230671
|texte= A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26230671" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |